How to perform a critical analysis of a randomised controlled trial

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 2, 2009, Pages 291-303

  Estellat, Candice ^a,b,c   Torgerson, David J ^d   Ravaud, Philippe ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

bias; evidence based medicine; randomisation; randomised controlled trial; sample size; selection bias

Indexed keywords

ANALYTIC METHOD; CLINICAL STUDY; CONFLICT OF INTEREST; DATA ANALYSIS; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOM SAMPLE; REVIEW; SAMPLE SIZE; SAMPLING; STATISTICAL ANALYSIS; SYSTEMATIC ERROR;

DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATOLOGY;

EID: 64749091915     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.03.003     Document Type: Review

References (32)

1. Guyatt G.H., Sackett D.L., and Cook D.J. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. J Am Med Assoc 270 (1993) 2598-2601
2. Guyatt G.H., Sackett D.L., and Cook D.J. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. J Am Med Assoc 271 (1994) 59-63
3. Moher D., Schulz K.F., and Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 285 (2001) 1987-1991
4. Greenhalgh T. Assessing the methodological quality of published papers. BMJ 315 (1997) 305-308
5. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007, Issue 2. Art No.:MR000012. doi:10.1002/14651858.MR000012.pub2.
6. Montori V.M., Bhandari M., Devereaux P.J., et al. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol 55 (2002) 787-790
7. Wood L., Egger M., Gluud L.L., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008) 601-605
8. Schulz K.F., and Grimes D.A. Blinding in randomised trials: hiding who got what. Lancet 359 (2002) 696-700
9. Boutron I., Estellat C., Guittet L., et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med 3 (2006) e425
10. Boutron I., Guittet L., Estellat C., et al. Reporting Methods of Blinding in Randomized Trials Assessing Nonpharmacological Treatments. PLoS Med 4 (2007) e61
11. Hollis S., and Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319 (1999) 670-674
12. Heritier S.R., Gebski V.J., and Keech A.C. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 179 (2003) 438-440
13. Bergholdt K., Fabricius R.N., and Bendix T. Better backs by better beds?. Spine 33 (2008) 703-708
14. Baron G., Boutron I., Giraudeau B., et al. Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. Arthritis Rheum 52 (2005) 1858-1865
15. Weinstein J.N., Tosteson T.D., Lurie J.D., et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. J Am Med Assoc 296 (2006) 2441-2450
16. Kyriakidi M., and Ioannidis J.P. Design and quality considerations for randomized controlled trials in systemic sclerosis. Arthritis Rheum 47 (2002) 73-81
17. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
18. Riggs B.L., Hodgson S.F., O'Fallon W.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322 (1990) 802-809
19. Chan A.W., Hrobjartsson A., Haahr M.T., et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. J Am Med Assoc 291 (2004) 2457-2465
20. Rothwell P.M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365 (2005) 176-186
21. Cook R.J., and Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 310 (1995) 452-454
22. Osiri M., Suarez-Almazor M.E., Wells G.A., et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 62 (2003) 316-321
23. Laupacis A., Sackett D.L., and Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988) 1728-1733
24. Keen H.I., Pile K., and Hill C.L. The prevalence of underpowered randomized clinical trials in rheumatology. J Rheumatol 32 (2005) 2083-2088
25. Guyatt G.H., Mills E.J., and Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med 5 (2008) e4
26. Altman D.G., and Bland J.M. Statistics notes. Units of analysis. BMJ 314 (1997) 1874
27. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol 38 (1998) 408-412
28. Rothwell P.M. External validity of randomised controlled trials: 'to whom do the results of this trial apply?. Lancet 365 (2005) 82-93
29. Farahani P., Levine M., Gaebel K., et al. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can J Clin Pharmacol 12 (2005) e254-e263
30. Ioannidis J.P., Evans S.J., Gotzsche P.C., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141 (2004) 781-788
31. Tugwell P., Judd M.G., Fries J.F., et al. Powering our way to the elusive side effect: a composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials. J Clin Epidemiol 58 (2005) 785-790
32. Rochon P.A., Gurwitz J.H., Simms R.W., et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154 (1994) 157-163